Ad hoc announcement pursuant to Art. 53 LR André C. Muller, current CEO of Idorsia, to retire and act as an advisor to the company to ensure a smooth transition Allschwil, Switzerland - June 10 ...

Ad hoc announcement pursuant to Art. 53 LR André C. Muller, current CEO of Idorsia, to retire and act as an advisor to the ...

Swiss pharma company Idorsia (SIX: IDIA) today announced the appointment of Dr Srishti Gupta as chief executive (CEO), ...

Idorsia Pharmaceuticals has claimed FDA approval for aprocitentan as a treatment for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that indication.

The Fabry disease market is growing due to rising prevalence and better diagnostics. While ERTs and GALAFOLD dominate, emerging gene therapies and new treatments show promise. However, pediatric ...

Through Ruth's story and expert insights from a sleep neurologist, explore why so many women silently endure insomnia during ...

Amicus Therapeutics is growing steadily with Galafold and a promising Pompe therapy, targeting $1B revenue by 2028. See why ...

and Idorsia Pharmaceuticals. Holding a postgraduate degree in Computer Science from École Polytechnique Fédérale de Lausanne, Büsser's expertise in machine learning has garnered him ...

Idorsia Ltd (SIX: IDIA) today announced the appointment of ... Dr. Gupta spent 18 years at McKinsey & Company as a senior leader in the pharmaceutical and global health practices. She has since served ...